Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 oral hPTH(1-34) dose-finding study in postmenopausal women with low bone mass
MOH_2019-06-25_007122Phase 2Active, not recruiting
- Sponsor
- Entera Bio Ltd.
- Start
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EB613 in osteopenia and osteoporosis (3 arms), sponsored by Entera Bio Ltd. Primary endpoint: Dose with best effect on bone formation. Started May 2019; status: active, not recruiting.
02
Drugs
EB613
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on MOH_2019-06-25_007122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-25_007122.